» Articles » PMID: 33445163

A Novel Multifunctional Gold Nanorod-mediated and Tumor-targeted Gene Silencing of GPC-3 Synergizes Photothermal Therapy for Liver Cancer

Overview
Journal Nanotechnology
Specialty Biotechnology
Date 2021 Jan 14
PMID 33445163
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-specific targeted delivery is a major obstacle to clinical treatment of hepatocellular carcinoma (HCC). Here we have developed a novel multi-functional nanostructure GAL-GNR-siGPC-3, which consists of Galactose (GAL) as the HCC-targeting moiety, golden nanorods (GNR) as a framework to destroy tumor cells under laser irradiation, and siRNA of Glypican-3 (siGPC-3) which induce specifically gene silence of GPC-3 in HCC. Glypican-3 (GPC-3) gene is highly associated with HCC and is a new potential target for HCC therapy. On the other hand, Gal can specifically bind to the asialoglycoprotein receptor which is highly expressed on membrane of hepatoma cells. GAL and siGPC-3 can induce targeted silencing of GPC-3 gene in hepatoma cells. In vivo and in vitro results showed that GAL-GNR-siGPC-3 could significantly induce downregulation of GPC-3 gene and inhibit the progression of HCC. More notably, GAL-GNR-siGPC-3 could induce both GPC-3 gene silencing and photothermal effects, and the synergistic treatment of tumors was more effective than individual treatments. In summary, GAL-GNR-siGPC-3 achieved a synergistic outcome to the treatment of cancer, which opens up a new approach for the development of clinical therapies for HCC.

Citing Articles

Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors.

Yang L, Wang H, Li S, Gan G, Deng W, Chang Y World J Gastroenterol. 2024; 30(11):1533-1544.

PMID: 38617449 PMC: 11008421. DOI: 10.3748/wjg.v30.i11.1533.


Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.

Liang Y, Wang B, Chen Q, Fu X, Jiang C, Lin Z Theranostics. 2023; 13(15):5452-5468.

PMID: 37908722 PMC: 10614686. DOI: 10.7150/thno.87498.


Gold Nanoparticles: Construction for Drug Delivery and Application in Cancer Immunotherapy.

Huang H, Liu R, Yang J, Dai J, Fan S, Pi J Pharmaceutics. 2023; 15(7).

PMID: 37514054 PMC: 10383270. DOI: 10.3390/pharmaceutics15071868.


The Role of Small Interfering RNAs in Hepatocellular Carcinoma.

Chen F, Zhang W, Gao X, Yuan H, Liu K J Gastrointest Cancer. 2023; 55(1):26-40.

PMID: 37432548 DOI: 10.1007/s12029-023-00911-w.


Triggering Immune System With Nanomaterials for Cancer Immunotherapy.

Li Q, Liu Y, Huang Z, Guo Y, Li Q Front Bioeng Biotechnol. 2022; 10:878524.

PMID: 35497343 PMC: 9046726. DOI: 10.3389/fbioe.2022.878524.